Palonosetron intravenous

Drug Profile

Palonosetron intravenous

Alternative Names: 2-QHBIQO; Aloxi Injection; Nuowei; ONICIT; Onicit; Palonosetron hydrochloride; Paloxi; RS-25259; RS-25259-197; RS-42358-197

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Roche Palo Alto LLC
  • Developer Helsinn; Taiho Pharmaceutical
  • Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting

Most Recent Events

  • 15 Feb 2017 Palonosetron intravenous licensed to Mundipharma in Iran, Pakistan, Indonesia and 30 countries in Africa
  • 30 Jun 2016 Taiho Pharmaceuticals plans a phase III trial for Chemotherapy induced nausea and vomiting (In infants, In children, In adolescents) in Japan (JapicCTI-163305)
  • 09 Mar 2016 Helsinn completes a phase III trial in Chemotherapy induced nausea and vomiting in Hungary, Lithuania and Greece (IV, Infusion) (EudraCT2015-001747-37)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top